Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder

This study is enrolling participants by invitation only.
Sponsor:
Information provided by (Responsible Party):
Axovant Sciences Ltd.
ClinicalTrials.gov Identifier:
NCT02871427
First received: August 15, 2016
Last updated: February 9, 2017
Last verified: February 2017
  Purpose
This study seeks to evaluate the long-term safety and effectiveness of nelotanserin for the treatment of visual hallucinations (VHs) and Rapid Eye Movement (REM) Sleep Behavior Disorder (RBD) in subjects with Lewy body dementia (LBD).

Condition Intervention Phase
Lewy Body Dementia
Dementia With Lewy Bodies
Parkinson's Disease Dementia
Visual Hallucinations
REM Sleep Behavior Disorder
Drug: Nelotanserin
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: An Open-label Study of Nelotanserin in Patients With Lewy Body Dementia Who Have Frequent Visual Hallucinations or REM Sleep Behavior Disorder

Resource links provided by NLM:


Further study details as provided by Axovant Sciences Ltd.:

Primary Outcome Measures:
  • Long-term safety and tolerability will be evaluated based on incidence of adverse events (AEs) and significant changes in physical examinations, vital signs, ECGs, and clinical laboratory assessments over time during treatment. [ Time Frame: 24 weeks ]
  • Long-term effectiveness will be evaluated based on change in the frequency and severity of visual hallucinations (as recorded by patient's caregiver) and/or REM sleep behaviors (based on a clinical evaluator) over time during treatment. [ Time Frame: 24 weeks ]

Estimated Enrollment: 80
Study Start Date: August 2016
Estimated Study Completion Date: July 2018
Estimated Primary Completion Date: July 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Nelotanserin
Once Daily, Oral, at 20, 40, 60, or 80 mg dose
Drug: Nelotanserin
Once Daily, Oral, at 20, 40, 60, or 80 mg dose

Detailed Description:
This is a multi-center open-label, long-term study in LBD subjects with RBD and/or VHs. Eligible subjects who completed a previous nelotanserin VH or RBD study and choose to participate in this open-label study will receive 20, 40, 60, or 80 mg nelotanserin once daily for 24 weeks.
  Eligibility

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects with LBD who completed a previous nelotanserin VH or RBD study

Exclusion Criteria:

  • Subjects with a current serious and/or unstable cardiovascular, respiratory, thyroid, gastrointestinal, renal, hematologic or other medical disorder
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02871427

Locations
United States, Florida
US114
Boca Raton, Florida, United States, 33486
US113
Orlando, Florida, United States, 32806
United States, Nebraska
US129
Lincoln, Nebraska, United States, 68526
United States, North Carolina
US101
Chapel Hill, North Carolina, United States, 27514
United States, Ohio
US104
Cleveland, Ohio, United States, 44195
US105
Columbus, Ohio, United States, 43210
Sponsors and Collaborators
Axovant Sciences Ltd.
Investigators
Study Director: Warren Wen Axovant Sciences, Inc., Clinical Research
  More Information

Additional Information:
Responsible Party: Axovant Sciences Ltd.
ClinicalTrials.gov Identifier: NCT02871427     History of Changes
Other Study ID Numbers: RVT-102-2003
Study First Received: August 15, 2016
Last Updated: February 9, 2017

Keywords provided by Axovant Sciences Ltd.:
Lewy body dementia
Dementia with Lewy bodies
Parkinson's disease dementia
Visual hallucinations
REM sleep behavior disorder

Additional relevant MeSH terms:
Disease
Parkinson Disease
Dementia
Alzheimer Disease
Lewy Body Disease
Mental Disorders
Hallucinations
REM Sleep Behavior Disorder
Pathologic Processes
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Neurocognitive Disorders
Tauopathies
Perceptual Disorders
Neurobehavioral Manifestations
Neurologic Manifestations
Signs and Symptoms
REM Sleep Parasomnias
Parasomnias
Sleep Wake Disorders

ClinicalTrials.gov processed this record on April 24, 2017